Form 4: Axogen Director William Burke Receives Annual Equity Grant of Restricted Stock Units

Axogen, Inc. Director William P. Burke was granted 14,150 restricted stock units as part of his annual equity compensation, valued at $150,000, which will vest on June 19, 2026.

Summary

• William P. Burke, a Director of Axogen, Inc. (AXGN), received an annual equity grant of 14,150 Restricted Stock Units (RSUs) on June 19, 2025.
• Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.
• The grant is valued at $150,000 as of the grant date.
• These RSUs are scheduled to vest on June 19, 2026, which is the one-year anniversary of the grant date.
• Following this transaction, Mr. Burke beneficially owns 14,150 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation event for a director, which is a positive for aligning interests but does not indicate significant new financial performance or strategic shifts for the company.

Positives

• The equity grant aligns the interests of Director William P. Burke with those of Axogen, Inc. shareholders, as his compensation is tied to the company's future stock performance.
• This is a standard practice for director compensation, indicating routine corporate governance and compensation policies are in place.

Future Outlook

The Restricted Stock Units granted to Director William P. Burke are scheduled to vest on June 19, 2026, indicating a future milestone for the conversion of these units into common stock.

Management Comments

• The grant of 14,150 Restricted Stock Units is described as an 'Annual equity grant for service as Director on the Axogen, Inc. Board of Directors.'
• The number of shares pursuant to the equity grant is based on a '$150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.'

Industry Context

The granting of restricted stock units to board members is a common practice in the biotechnology and medical device industries, serving as a form of non-cash compensation that aligns director incentives with long-term shareholder value creation. This filing reflects a routine compensation event within the industry.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely accepted practice across various industries, including healthcare and biotechnology, aligning with corporate governance best practices.
• While specific comparable companies or projects are not detailed in this Form 4, the structure of an annual equity grant with a one-year vesting period is typical for non-employee director compensation in publicly traded companies of similar size and sector to Axogen, Inc.

Corporate Governance

Related Party Transactions

• The grant of 14,150 Restricted Stock Units to William P. Burke, a Director of Axogen, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board. This is a routine and disclosed compensation event.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The 14,150 Restricted Stock Units granted to Director William P. Burke are expected to vest on June 19, 2026, at which point they will convert into shares of Axogen, Inc. common stock.

Key Dates

Keywords

Axogen, AXGN, Form 4, Insider Transaction, Restricted Stock Units, Equity Grant, Director Compensation, Corporate Governance